Are you Dr. Shepard?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 82 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4220 Harding Pike
SE Building Suite 200
Nashville, TN 37205Phone+1 615-385-3751Fax+1 615-269-7085- Is this information wrong?
Summary
- Dr. Gregg Shepard, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee and North Carolina. He is affiliated with Ascension Saint Thomas, Ascension Saint Thomas, and Southern Tennessee Regional Health System-Lawrenceburg.
Education & Training
- Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- Wake Forest University School of MedicineResidency, Internal Medicine, 2002 - 2005
- University of Tennessee Health Science Center College of MedicineClass of 2002
Certifications & Licensure
- TN State Medical License 2008 - 2026
- NC State Medical License 2002 - 2009
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 84 citationsA phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C. Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B. Weir, Gregg C. Shepard, Jeffrey T. Williams, Mythili Shastry, Howard A. Burris, John D. Hainsworth> ;Journal of Neuro-Oncology. 2016 Jun 16
- 64 citationsPhase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.John D. Hainsworth, Kent C. Shih, Gregg C. Shepard, Guy W Tillinghast, Brett T Brinker, David R. Spigel> ;Clinical Advances in Hematology & Oncology. 2012 Apr 1
- 8 citationsBsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.G. C. Shepard, H. L. Lawson, Gregory A. Hawkins, J. Owen> ;International Journal of Laboratory Hematology. 2011 Jun 1
Professional Memberships
- Member
Hospital Affiliations
- Ascension Saint ThomasNashville, Tennessee
- Southern Tennessee Regional Health System-LawrenceburgLawrenceburg, Tennessee
- Ascension Saint ThomasNashville, Tennessee